Literature DB >> 10783826

Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.

S Neuhoff1, P Langguth, C Dressler, T B Andersson, C G Regårdh, H Spahn-Langguth.   

Abstract

OBJECTIVES: The multidrug transporter P-glycoprotein (P-gp) appears to play a significant role in drug absorption and disposition. Hence, it is of interest to evaluate structure-affinity relationships for the purpose of making predictions.
METHODS: The affinity to P-gp of related molecular structures from various groups of drugs was determined using competitive radioligand-binding assays. Structural analogs, stereoisomers and metabolites of verapamil-type calcium antagonists, beta-adrenoceptor antagonists as well as omeprazole, omeprazole enantiomers and the sulfone metabolite of omeprazole were investigated.
RESULTS: Whereas some stereoselectivity was detected for the high-affinity P-gp substrates verapamil and carvedilol, little or no differences were observed in the case of other beta-blockers. One of the 4 labetalol stereoisomers, the R,R-isomer dilevalol, had an IC50 value half that of labetalol.
CONCLUSIONS: Metabolites of verapamil, gallopamil, carvedilol and omeprazole are characterized by having higher IC50 values (lower P-gp affinity) than the respective parent compounds. Only the acebutolol metabolite, diacetolol, had a P-gp affinity comparable to that of the parent compound.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783826     DOI: 10.5414/cpp38168

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  8 in total

1.  Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects.

Authors:  Li-Mei Zhao; Xiao-Jing He; Feng Qiu; Ya-Xin Sun; Jesse Li-Ling
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

2.  Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells.

Authors:  Lei Zhang; Yan Yan; Difeng Zhu; Wei Yang; Weisi Wang; Yongzhou Hu; Bo Yang; Qiaojun He
Journal:  Invest New Drugs       Date:  2010-08-05       Impact factor: 3.850

3.  New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.

Authors:  Joost Bart; Eli C F Dijkers; Theodora D Wegman; Elisabeth G E de Vries; Winette T A van der Graaf; Harry J M Groen; Willem Vaalburg; Antoon T M Willemsen; N Harry Hendrikse
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

Review 4.  Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.

Authors:  Philip H Elsinga; N Harry Hendrikse; Joost Bart; Aren van Waarde; Willem Vaalburg
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

Review 5.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

6.  The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.

Authors:  Tomonori Tateishi; Masatomo Miura; Toshio Suzuki; Tsukasa Uno
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

7.  Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption.

Authors:  Wen Kou; Jasleen K Sodhi; Xin'an Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2021-04-13       Impact factor: 4.200

8.  Fexofenadine hydrochloride in the treatment of allergic disease: a review.

Authors:  David Axelrod; Leonard Bielory
Journal:  J Asthma Allergy       Date:  2008-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.